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Production of fuels and chemicals through microbial fermentation of plant material is a desirable alternative to petrochemical-
based production. Fermentative production of biorenewable fuels and chemicals requires the engineering of biocatalysts that can
quickly and eﬃciently convert sugars to target products at a cost that is competitive with existing petrochemical-based processes.
It is also important that biocatalysts be robust to extreme fermentation conditions, biomass-derived inhibitors, and their target
products. Traditional metabolic engineering has made great advances in this area, but synthetic biology has contributed and will
continue to contribute to this field, particularly with next-generation biofuels. This work reviews the use of metabolic engineering
and synthetic biology in biocatalyst engineering for biorenewable fuels and chemicals production, such as ethanol, butanol, acetate,
lactate, succinate, alanine, and xylitol. We also examine the existing challenges in this area and discuss strategies for improving
biocatalyst tolerance to chemical inhibitors.
1. Introduction
Human society has always depended on biomass-derived
carbon and energy for nutrition and survival. In recent
history, we have also become dependent on petroleum-
derived carbon and energy for commodity chemicals and
fuels. However, the nonrenewable nature of petroleum stands
in stark contrast to the renewable carbon and energy present
in biomass, where biomass is essentially a temporary storage
unit for atmospheric carbon and sunlight-derived energy.
Thus there is increasing demand to develop and implement
strategies for production of commodity chemicals and fuels
from biomass instead of petroleum. Specifically, in this work
we are interested in the microbial fermentation of biomass-
derived sugars to commodity fuels and chemicals.
In order for a fermentation process to compete with
existing petroleum-based processes, the target chemical must
be produced at a high yield, titer and productivity. Some-
times there are additional constraints on the fermentation
process, such as the presence of potent inhibitors in biomass
hydrolysate or the need to operate at an extreme pH or
temperature [1]. These goals can be diﬃcult to attain with
naturally-occurring microbes. Therefore, microorganisms
with these desired traits often must be developed, either by
modification of existing microbes or by the de novo design
of new microbes. While significant progress has been made
towards de novo design [2, 3], this work focuses on the
modification of existing microbes.
Humanity has long relied on microbial biocatalysts for
production of fermented food and beverages and eukaryotic
biocatalysts for food and textiles. We have slowly modified
these biocatalysts by selecting for desirable traits without
understanding the underlying biological mechanisms. But
upon elucidation of the biological code and the development
of recombinant DNA technology, we now have the tools to
do more than just select for observable traits—we are now
able to rationally modify and design metabolic pathways,
proteins, and even whole organisms.
Much of this rational modification has been in the
form of Metabolic Engineering. Metabolic Engineering was
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Figure 1: Overview of tools for metabolic redesign.
defined in 1991 [4, 5] and here we use the definition of
“the directed improvement of production, formation, or cellular
properties through the modification of specific biochemical
reactions or the introduction of new ones with the use of recom-
binant DNA technology ” [6]. While Metabolic Engineering
has enabled extraordinary advances in the production of
commodity chemicals and fuels from biomass, some of
which are discussed in this work, we have now reached the
point where biological functions that do not exist in nature
are desired. Synthetic biology aims to develop and provide
these nonnatural biological functions.
For many years, the term Synthetic Biology was used to
describe concepts that would be classified today as Metabolic
Engineering [7]. However in the last 10 years, terms such as
“unnatural organic molecules” [7], “unnatural chemical sys-
tems [8], “novel behaviors” [9], “artificial, biology-inspired
systems” [10], and “functions that do not exist in nature”
[11] have been used to describe Synthetic Biology. For the
purpose of this review, we will apply the Synthetic Biology
definition of “the design and construction of new biological
components, such as enzymes, genetic circuits, and cells, or the
redesign of existing biological systems” [12].
Synthetic biology has application to many fields, includ-
ing cell-free synthesis [13], tissue and plant engineering [14]
and drug discovery [15], but here we are interested in the
modification of microbes for the biorenewable production
of commodity chemicals and fuels. Other recent reviews have
also dealt with this topic [16–18].
Synthetic biology for the production of a target com-
pound can be expressed as a sequence of the following
events, each of which will be discussed in more detail and
demonstrated below. (1) Design the metabolic pathways
and phenotypic properties of the desired system. What are
the desired substrates and products? What are the expected
environmental stressors? (2) Choose an appropriate host
organism (chassis) based on the following criteria. Which
organisms display at least some of the desired properties?
How well characterized and annotated are these organisms?
Are there molecular biology tools for modification of this
chassis? (3) Formulate an implementation approach. What
modifications are necessary to achieve the pathways and
properties identified in step (1)? Do metabolic pathways need
to be added, removed, or tuned? Does the desired pathway
or phenotype exist in nature, or does it need to be designed
de novo? (4) Optimize the redesigned system and assess the
system properties relative to the ideal. Can the chassis be
improved further?
Even a simple biocatalyst, such as the laboratory work-
horse Escherichia coli, is a complex system of an estimated
4603 genes, 2077 reactions, and 1039 unique metabolites
[19, 20], and while the steps outlined above are relatively
straightforward, it is still diﬃcult to quickly and reliably
engineer a biocatalyst to perform desired behaviors [21].
Systems biology, the standardization of biological systems,
and metabolic evolution are all vital to the compensation for
this disconnect between the expected and actual biocatalyst
behaviors. Through a combination of these powerful tech-
niques, biocatalysts have been redesigned for the production
of an astounding array of commodity fuels and chemicals,
both natural and unnatural (Figure 1 and Table 1). Here
we discuss successful examples involving the production of
commodity fuels and chemicals, with a focus on D- and L-
lactate, L-alanine, succinate, ethanol, and butanol.
2. Methods and Tools for Biocatalyst Redesign
2.1. Chassis. A robust and stable chassis enables eﬃcient
and economical production of fuels and chemicals at an
industrial level. Since we are specifically interested in bio-
catalysts that can utilize biomass, a desirable chassis has
the following characteristics: (1) growth in mineral salts
medium with inexpensive carbon sources, (2) utilization of
hexose and pentose sugars, so that all the sugar components
in lignocellulosic biomass can be converted to the desired
product, (3) high metabolic rate, essential for high rate
of productivity, (4) simple fermentation process to reduce
the manipulation cost and minimize failure risks in large-
scale production, (5) robust organism (high temperature
and low pH where possible) to reduce the requirement for
external cellulase during cellulose degradation, as well as
to reduce the required amount of base addition, (6) ease
of genetic manipulation and genetic stability, (7) resistance
to inhibitors produced during the biomass pretreatment
process, and (8) tolerance to high substrate and product
concentrations in order to obtain high titers of target
compound.
Enteric bacteria, especially E. coli, have many of the above
mentioned physiological characteristics and are, thus, an
excellent chassis for synthetic biology. Most of the examples
discussed here use E. coli, but other important microbial
model systems have been redesigned, including Clostridium
acetobutylicum [28], Corynebacterium glutamicum [29], Sac-
charomyces cerevisiae [30], and Aspergillus niger [31]. E. coli
has been used as a model organism since the beginning
of genetic engineering [32]. While K-12 strain MG1655
(ATCC# 47076) is one of the most commonly used E. coli
strains [33], there are other lineages, such as B (ATCC#
11303), C (ATCC# 8739), and W (ATCC# 9637), that are
also generally regarded as safe since they are unable to
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Table 1: Summary of engineered E. coli biocatalysts for production of renewable fuels and chemicals in our laboratory.
Product Fermentation condition(1) Titer (g/L) Yield(g/g) Productivity (g/L/h) Reference
Redesign through modification of existing pathways
D-lactate Anaerobic, batch 118 0.98 2.88 [22]
Acetate Aerobic, fed-batch 53 0.50 1.38 [23]
Succinate Anaerobic, batch 83 0.98 0.90 [24]
Redesign through introduction of foreign pathways
Ethanol Anaerobic, batch 43 0.48 2.00 [25]
L-lactate Anaerobic, batch 116 0.98 2.29 [22]
Xylitol Aerobic, fed-batch 38 1.40 0.81 [26]
L-alanine Anaerobic, batch 114 0.95 2.38 [27]
(1)
All fermentations were done in mineral salts medium with glucose, except for the ethanol fermentations which used xylose.
colonize the human gut [34]. Although K-12 is the most
characterized and widely used strain, E. coli W (ATCC# 9637)
and C (ATCC# 8739) have proven to be better chassis for
synthesizing fuels and chemicals. For example, K-12-derived
strains were unable to completely ferment 10% (w/v) glucose
in either complex or mineral salts medium [1, 35], while
derivatives of strains W or C can completely ferment more
than 10% (w/v) of glucose with higher cell growth and sugar
utilization rates than K-12. Additionally, E. coli W strains
have the native ability to ferment sucrose [1, 36].
Foreign genes may be unstable in host cells due to
recombination facilitated by mobile DNA elements, and thus
the mobile DNA elements in E. coli K-12 strain have been
deleted [37]. This minimal genome construction strategy
is an excellent approach to improve this chassis for the
production of fuels and chemicals.
2.2. Systems Biology Tools
2.2.1. Genome-Scale Models and In Silico Simulation. Given
the rational basis of metabolic engineering and synthetic
biology, models and simulations are critical predictive
and tools. Genome sequencing and automatic annotation
tools have enabled construction of genome-scale metabolic
models of nearly 20 microorganisms [38]. These constraint-
based models and in silico simulations can be used to predict
metabolic flux redistribution after genetic manipulation,
or to predict other cellular functions, such as substrate
preference, outcomes of adaptive evolution and shifts in
expression profiles [39]. They can also aid in pathway design
to obtain desired phenotypes [40–42]. For example, the
E. coli iJE660a GSM model was used to successfully simulate
single- and multiple-gene knockouts to improve lycopene
production [42]. The computational framework, Optknock,
was developed to identify gene deletion targets for system
optimization [41], and simulation results for gene deletions
for succinate, lactate, and 1,3-propanediol production were
in agreement with experimental data. Another simulation
program, OptStrain, was developed to guide metabolic
pathway modification for target compound production,
through both the addition of heterologous metabolic reac-
tions and deletion of native reactions [40]. However, most
of the current models only have stoichiometric information,
while kinetic and regulatory eﬀects are not included [38,
39]. Integration of kinetic and regulatory information will
improve the accuracy and predictive power of these models.
2.2.2. High-Throughput Omics Analysis. High-throughput
omics analysis, such as transcriptome, proteome, meta-
bolome, and fluxome [43–45], aids in characterization of
cellular function on multiple levels, and therefore provide a
“debugging” capability for system optimization [12, 45].
Genetic manipulations can disturb the metabolic balance
or impair cell growth due to depletion of important pre-
cursors [46, 47], accumulation of toxic intermediates [48],
or redox imbalance [1]. For example, high NADH levels in
E. coli reengineered for ethanol production inhibited citrate
synthase activity, thereby limiting cell growth by lowering
production of the critical metabolite 2-ketoglutarate [49].
Metabolome and fluxome analysis can quickly identify the
limiting metabolites or altered metabolic flux distribution,
providing the basis for problem solving [45, 50]. For
example, metabolite measurements of Aspergillus terreus
were implemented in the rational metabolic redesign for
increased production of lovastatin [45, 50]. Changes of
mRNA and protein profiles can be identified by tran-
scriptome and proteome analysis, providing gene targets
for further engineering [46, 47]. The work of Choi et al.
demonstrate this concept: transcriptome analysis of E. coli
producing the human insulin-like growth factor I fusion
protein aided in selection for targets for gene deletion.
The resulting redesigned strain showed a greater than 2-
fold increase in product titer and volumetric productivity
[46, 47]. Additionally, comparative genome sequence anal-
ysis facilitates identification of mutated genes or regula-
tors during evolution, and these mutations can be used
to redesign the systems for better synthetic capability.
For example, in an eﬀort described as “genome-based
strain reconstruction”, evolved strains of Corneybacterium
glutamicum selected for L-lysine production were com-
pared to the parental strain, and mutations were found
that were proposed as beneficial to L-lysine production.
Three of these mutations were introduced into the parent
strain and enabled production of up to 3.0 g/L/hr L-lysine
[51].
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Figure 2: Comparison of three-gene deletion methods in E. coli. These methods can also be used in other enteric bacteria. The first and third
methods can also be used for gene integration into the chromosome and promoter replacement for tuning gene expression. 2(a) plasmid-
based method. Step 1 is construction of the deletion plasmid containing DNA fragments homologous to the target gene (h1 and h2), a
selectable marker, and either a temperature sensitive or conditional replicon. Step 2 is double-crossover recombination; the plasmid cannot
replicate in the host strain, and antibiotic-resistant colonies are selected. In step 3, the FRT, replicon, and antibiotic resistance marker are
removed by FLP. 2(b) Linear DNA-based method. Step 1 is construction of the linear DNA fragment by PCR (H1-P1 and H2-P2 as primers).
H1 and H2 refer to short DNA fragments homologous to target gene. Step 2 is replacement of the target gene with the antibiotic resistance
gene through crossover recombination with the help of Red recombinase. Step 3 is removal of FRT and antibiotic marker by FLP. 2(c) Two-
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Step 6 is the second recombination step, in which the cat, sacB cassette is removed by selection on sucrose.
Journal of Biomedicine and Biotechnology 5
2.3. Genetic Manipulation Tools
2.3.1. Gene Deletion. Gene deletion can redistribute carbon
flux toward the target product by deleting genes critical to
competing metabolic pathways and, thus, is widely used in
metabolic redesign strategies. Homologous recombination
is the most frequently used strategy for gene-deletion
(Figure 2). Historically, plasmids containing a selectable
marker flanked by DNA fragments homologous to the
target gene and either temperature sensitive or conditional
replicons were needed for eﬃcient gene deletion in bacteria
[52] (Figure 2(a)). In contrast, genes can be directly dis-
rupted in yeast by linear PCR fragments with short flanking
DNA fragments homologous to chromosomal DNA. Linear
DNA is not as easy to transform into E. coli because of
the intracellular exonuclease system and low recombination
eﬃciency. Gene deletion systems based on bacteriophage
λ Red recombinase facilitate chromosomal gene deletion
using a linear PCR fragment [53]. In this method, the
chromosomal gene is replaced by the selectable marker
flanked by two FRT (FLP recognition target) fragments
(Figure 2(b)) and then the marker can be removed by the
FLP recombinase [54]. However, this method leaves a 68bp-
FRT scar on the chromosome after each excision [52],
reducing further gene deletion eﬃciency. Repeated use of this
FRT/FLP system for specific gene deletions has the potential
to generate large unintended chromosomal deletions.
To facilitate sequential gene deletions, our lab has
developed a two-stage recombination strategy (Figure 2(c)),
using the sensitivity of E. coli to sucrose when Bacillus
subtilis levansucrase (sacB) is expressed [24, 27, 55]. Gene
deletions created by this method do not leave foreign DNA,
antibiotic resistance markers, or scar sequences at the site of
deletion. In the first recombination, part of the target gene
is replaced by a DNA cassette containing a chloramphenicol
resistance gene (cat) and levansucrase gene (sacB). In the
second recombination, the cat, sacB cassette is removed by
selection for resistance to sucrose. Cells containing the sacB
gene accumulate levan during incubation with sucrose and
are killed [55]. Surviving recombinants are highly enriched
for loss of the cat, sacB cassette [24, 27].
2.3.2. Gene Expression Tuning. Like gene deletions, plasmid-
based expression systems are ubiquitous to metabolic
redesign. However, plasmid-based systems have several dis-
advantages. (1) Plasmid maintenance is a metabolic burden
on the host cell, especially for high-copy number plasmids
[56]. Note that high copy numbers are not essential, consid-
ering that most central metabolic enzymes are encoded by
a single gene; (2) plasmid-based expression is dependent on
plasmid stability, with only few natural unit-copy plasmids
having the desired stability [12]; (3) only low-copy number
plasmids have replication that is timed with the cell cycle,
and thus maintaining a consistent copy number in all
cells is challenging [12]; (4) metabolic redesign can require
construction of a complex heterologous pathway, and thus
several genes, encoded in large pieces of DNA, need to be
incorporated. Most commercial plasmids have diﬃculties
carrying large DNA fragments.
Chromosomal integration of the target genes followed by
fine-tuning their expression could eliminate these plasmid-
associated problems. The abovementioned two-step recom-
bination strategy for gene deletion can also be used for gene
integration or promoter replacement (Figure 2).
Gene expression in prokaryotes is mainly controlled at
the transcriptional level, and therefore the promoter is the
most tunable element. While inducible promoters, such as
lac and ara, have been traditionally used to modulate gene
expression, large-scale inducer use is cost prohibitive for
production of fuels and bulk chemicals. However, several
strategies have been developed to construct constitutive
promoter libraries for fine-tuning gene expression. Some
methods rely on the use of natural promoters. For example,
Zymomonas mobilis genomic DNA was used to construct
a promoter library for screening optimal expression of
Erwinia chrysanthemi endoglucanase genes (celY and celZ) in
Klebsiella oxytoca P2 in order to improve ethanol production
from cellulose [57]. Other methods rely on random mod-
ification of existing promoters, such as the randomization
of the spacer sequences between the consensus sequences
[58], or mutagenesis of a constitutive promoter [59]. This
promoter modification method was used to assess the
impact of phosphoenolpyruvate carboxylase levels on cell
yield and deoxy-xylulose-P synthase levels on lycopene
production, and the optimal expression levels of these genes
were identified for maximal desired phenotype [59]. These
synthetic promoter libraries could also be integrated into
the chromosome directly, which could facilitate expression
modulation of chromosomal genes [60, 61].
The fine-tuning methods described above rely on the
selection of the best natural promoter or random alteration
of existing promoters. One of the goals of synthetic biology
is construction of standard parts, and posttranscriptional
processes, such as transcriptional termination, mRNA degra-
dation, and translation initiation, have been engineered
with this goal in mind. Examples include construction of a
synthetic library of 5’ secondary structures to successfully
manipulate mRNA stability [62], and modulation of the
ribosome binding site (RBS) as well as Shine-Dalgarno
(SD) and AU-rich sequences to tune gene expression at the
translation initiation process [60, 63]. Riboregulators were
also developed to tune gene expression via RNA-RNA inter-
actions [64]. A final method of fine-tuning gene expression
is codon optimization, which can improve translation of
foreign genes [65]. These optimized gene sequences often
do not exist in nature and must be generated using DNA
synthesis techniques.
In many cases, more than one gene needs to be intro-
duced into the chassis and expression of these genes needs
to be coordinated to attain desired biocatalyst performance.
One such method is modulation of the expression of each
individual gene via its own promoter. However, it is diﬃcult
to predict the appropriate expression level of each gene.
Another option is to combine multiple genes into a synthetic
operon with a single promoter, and fine-tune expression
of each gene through posttranscriptional processes [12]
with tunable control elements (such as mRNA secondary
structure, RNase cleavage sites, ribosome binding sites, and
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sequestering sequences) at intergenic regions. Libraries of
tunable intergenic regions (TIGRs) were generated and
screened to tune expression of several genes in an operon
[48]. This method was used to coordinate expression of three
genes in an operon that encodes a heterologous mevalonate
biosynthetic pathway, improving mevalonate production by
7-fold [48]. Another method to control expression of more
than one gene is to engineer global transcription machinery
by random mutagenesis of transcription factors [66, 67].
This method was shown to eﬃciently improve tolerance to
toxic compounds and production of metabolites, and to alter
phenotypes [66, 67].
2.3.3. Protein Engineering. Natural proteins may not meet
the required criteria for specific and eﬃcient system perfor-
mance, and thus alteration for a specific application may
be needed. Directed evolution of proteins oﬀers a way to
rapidly optimize enzymes, even in the absence of structural
or mechanistic information [68]. For directed evolution, a
protein library is usually generated by random mutagenesis
[68], recombination of a target gene [69], or a family
of related genes [70] and then the library is analyzed by
high-throughput screening. This method has been used to
successfully increase enzyme activity [71, 72], increase pro-
tein solubility and expression, invert enantioselectivity, and
increase stability and activity in unusual environments [68].
For example, a mutation library of the gene-encoding ger-
anylgeranyl diphosphate synthase of Archaeoglobus fulgidus
was generated to screen for mutants with higher activity,
enabling lycopene production in E. coli. Screening of more
than 2,000 variants identified eight with increased activity;
one of which increased lycopene production by 100% [71].
Of particular relevance to the field of synthetic biology
is the creation of novel enzymatic activity through protein
engineering [73, 74]. For example, the unnatural isomer-
ization of α-alanine to β-alanine was attained by evolving a
lysine 2,3-aminomutase to expand its substrate specificity to
include α-alanine [73].
Rational design is another powerful tool to increase
protein properties, especially with the aid of computational
analysis [75, 76]. Based on knowledge of protein structure
and function, one can predict which amino acid(s) to change
in order to obtain the desired function. In the redesign of
Lactobacillus brevis for the production of secondary alcohols,
it was desired to change the cofactor preference of the R-
specific alcohol dehydrogenase from NADPH to NADH. A
structure-based computational model was used to identify
potentially beneficial amino acid substitutions and one of
these changes increased NADH-dependent activity four-fold
[77].
While these examples demonstrate the power of ratio-
nal enzyme (re-)design, this approach requires detailed
information about the protein structure and mechanism,
while random mutagenesis does not. Recent advances have
combined directed evolution and rational design in a so-
called “semi-rational” approach to successfully improve
enzyme activity when only limited information is available
[78, 79]. When the mutagenesis is limited to specific residues,
as chosen from existing structural or functional knowledge,
these “smart” libraries are more likely to yield positive
results [79]. For example, the catalytic activity of pyranose-
2-oxidase was improved by mutagenesis of the known active
site [80].
While the 20 natural amino acids supply enzymes with a
wide range of possible activity, this range can be expanded
even further by the use of unnatural amino acids (UAAs).
There are more than 40 UAAs available at this time and
they have been used to probe protein function, photocage
critical residues, and alter metalloprotein properties [81, 82].
While this technology is still in the developmental stage,
at least one study has shown an improvement in enzyme
activity following insertion of UAAs. Site 124 of E. coli’s
nitroreductase was replaced with a variety of natural and
unnatural amino acids and certain UAA variants had a
greater than 2-fold increase in activity over the best natural
amino acid variant [83]. This biomimetic approach has been
expanded to other metabolites, such as carbohydrates [84]
and lipids [85].
2.4. Evolution. As described above, a robust biocatalyst with
high yield, titer, and productivity is critical for a fermentation
process to compete with petrochemical-based production.
Current models and simulation tools provide a framework
given the constraints of known protein functions. But the
many reactions and enzymes that remain uncharacterized
cannot be included in this theoretical analysis. Therefore
rational design methods often result in a biocatalyst that
performs poorly relative to the model. Metabolic evolution
provides a complementary approach to improve biocatalyst
productivity and robustness, dependent upon the design of
an appropriate selection pressure. Where feasible, synthesis
of the target compound can be coupled to the production
of ATP, redox balance, or key metabolites that are essential
for growth, and selection for improvements in growth during
metabolic evolution (serial transfers) can be used to coselect
for higher rates or titers of target compounds (Figure 3).
Both redox balance and net ATP production in such a
synthetic system are requisites for successful evolution.
We have used this metabolic evolution strategy to
optimize biocatalysts redesigned for production of several
fermentation products [1], including ethanol, D-lactate, L-
lactate, L-alanine (Figure 3), and succinate, as described in
more detail below. A frequently-used design scheme is to
couple synthesis of the target product to growth by inactivat-
ing competing NADH-consuming pathways. Thus, the only
way for cells to regenerate NAD+ for glycolysis is to produce
the target compound. Increased cell growth, supported by
higher ATP production rate during glycolysis, is coupled
with higher NADH oxidization rate, and thus tightly coupled
with synthesis of target product. This evolution strategy has
been shown to increase productivity by up to two orders of
magnitude.
Computational frameworks based on genome-scale
metabolic models have been used to construct biocatalysts
that couple biomass formation with chemical production
[40, 41], and therefore provide a basis for selective pressure
for high productivity. For example, Optknock identified gene
deletion targets for the construction of lactate-producing
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Figure 3: Metabolic evolution for improving L-alanine production in E. coli [27]. 3(a) Redesigned metabolic pathway for L-alanine
production: ATP production and cell growth is coupled to NADH oxidation and L-alanine production. 3(b) Directed evolution improves
cell growth. Parental strain XZ112 reaches a maximum cell mass of 0.7 gL−1 after 48 hours of fermentation; evolved strain XZ113 attains
0.7 gL−1 after 24 hours and a maximum of 0.9 gL−1 after 48 hours; 3(c) metabolic evolution to improve cell growth also improves alanine
production. Parental strain XZ112 produces 355 mM alanine after 72 hours of fermentation; evolved strain XZ113 produces 484 mM in 48
hours.
E. coli, and then directed evolution improved production
capability [86]. Although rational design of metabolic
pathways based on current metabolic models is a common
method for maximizing yield of the target compound,
this method is not always the best strategy, due to our
limited understanding of the complicated metabolic network
and dynamic kinetics of each reaction. Metabolic evolu-
tion provides an excellent alternative method for strain
improvement, through which reactions that are not currently
predictable would be selected to improve biocatalyst perfor-
mance [87]. As our knowledge of biocatalyst behavior and
metabolism improves, predictive models will become even
more powerful.
3. Redesign through Modification of
Existing Pathways
In this section, we highlight projects that have redesigned a
chassis to produce target compounds at high yield and titer
without the introduction of foreign pathways. In the next
section, we describe biocatalyst redesigns which used foreign
or nonnatural pathways.
3.1. Succinate. Succinate, a four-carbon dicarboxylic acid,
is currently used as a specialty chemical in food, agri-
cultural, and pharmaceutical industries [88] but can also
serve as a starting point for the synthesis of commodity
chemicals used in plastics and solvents, with a potential
global market of $15 billion [89]. Succinate is primarily
produced from petroleum and there is considerable interest
in the fermentative production of succinate from sugars
[89].
Several rumen bacteria can produce succinate from
sugars with a high yield and productivity [90–92], but
require complex nutrients. Alternatively, native strains of
E. coli ferment glucose eﬀectively in simple mineral salts
medium but produce succinate only as a minor product [93].
Therefore E. coli strain C (ATCC 8739) was redesigned for
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succinate production at high yield, titer, and productivity
[94].
The initial redesign strategy focused on inactivation of
competitive pathways, specifically deletion of lactate dehy-
drogenase (ldhA), alcohol/aldehyde dehydrogenase (adhE),
and acetate kinase (ackA). However, the resulting strain grew
poorly in mineral salts medium under anaerobic condition
and accumulated only trace amounts of succinate. Because
NADH oxidization is coupled to succinate synthesis in this
strain, metabolic evolution was used to improve both the
cell growth and succinate production. After inactivation
of pyruvate formate-lyase and methylglyoxal synthase to
eliminate formate and lactate production, the final strain,
KJ073, produced near 670 mM succinate (80 g/L) in mineral
salts medium with a high yield (1.2 mol/mol glucose) and
high productivity (0.82 g/L/h) [94]. Inactivation of threonine
decarboxylase (tdcD), 2-ketobutyrate formate-lyase (tdcE),
and aspartate aminotransferase (aspC) further increased
succinate yield (1.5 mol/mol glucose), titer (700 mM), and
productivity (0.9 g/L/h) [24].
Despite its power in improving biocatalyst performance,
metabolic evolution has the undesirable property of being
a black box; evolved strains show the desired biocatalyst
properties, but the metabolic evolution process does not
improve our understanding of the biocatalyst. Therefore,
reverse engineering of evolved strains can help us identify
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key mutations that can then be rationally applied to other
biocatalysts. Reverse engineering of the succinate-producing
strain revealed two significant changes in cellular metabolism
that increased energy eﬃciency [87]. The first change is
that PEP carboxykinase (pck), which normally functions in
gluconeogenesis during the oxidative metabolism of organic
acids [90, 95, 96], became the major carboxylation pathway
for succinate production. High-level expression of PCK
dominated CO2 fixation and increased ATP yield (1 ATP
per oxaloacetate produced). The second change is that
the native phosphoenolpyruvate- (PEP-) dependent phos-
photransferase system for glucose uptake was inactivated
and replaced by an alternative glucose uptake pathway:
GalP permease (galP) and glucokinase (glk). These changes
increased the pool of PEP available for maintaining redox
balance, as well as increasing energy eﬃciency by eliminating
the need to produce additional PEP from pyruvate, a reaction
that requires two ATP equivalents [97].
While rational design based on current metabolic under-
standing is a key component of metabolic engineering
and synthetic biology, our limited understanding of the
complicated metabolic network and dynamic kinetics of each
reaction can lead to failure of predictive models. In this
example, metabolic evolution was demonstrated as an excel-
lent alternative method for strain improvement, through
which currently unpredictable reactions would be selected to
expand cellular metabolic capability [87]. By understanding
the mutations that enabled desirable performance of the
succinate-producing strain, we have more options available
for the redesign of future systems. To demonstrate this,
E. coli was again redesigned based on the findings from
the evolved strain [98]. This time, the design strategy shifted
from inactivating competitive fermentation pathways to
recruiting energy conserving pathways for eﬃcient succinate
production (Figure 4(e)). After increasing pck gene expres-
sion and inactivating the native glucose PTS system, the
native E. coli metabolic system was converted to an eﬃcient
succinate synthetic system, equivalent to the native pathway
of succinate-producing rumen bacteria [98].
3.2. D-Lactate. D-lactate is widely used as a specialty
chemical in the food and pharmaceutical industry. It can
also be combined with L-lactate for the production of
polylactic acid (PLA), an increasingly popular biorenewable
and biodegradable plastic [99, 100] whose commercial
success obviously depends on the production cost. Although
glucose is the current substrate for fermentative production
of lactate, it is desirable to produce this commodity chemical
from lignocellulosic feedstock, which contains a mixture
of sugars. Some lactic acid bacteria have the desirable
native ability to produce large amount of D-lactate under
low pH condition, where the low pH reduces the process
cost [101, 102]. However, these lactic acid bacteria require
complex nutrients, and many of them lack the ability to
ferment pentose sugars. The lactic acid bacteria that do
ferment pentose sugars unfortunately produce a mixture
of lactate and acetate and, thus, are not a good chassis
for commercial production of D-lactate. While E. coli can
ferment many sugars eﬀectively in a simple mineral salts
medium, inherent D-lactate productivity is low and other
undesirable metabolites are also produced [103]. Therefore,
the E. coli metabolic system was redesigned to attain
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the desired properties of high yield and productivity of
D-lactate.
E. coli strain W3110 was used as the chassis for D-
lactate production with a redesign strategy that focused on
inactivation of competitive fermentation pathways [104].
After deleting the genes encoding fumarate reductase (frd-
ABCD), alcohol/aldehyde dehydrogenase (adhE), pyruvate
formate lyase (pflB), and acetate kinase (ackA), the resulting
strain, SZ63, can only oxidize NADH via D-lactate synthesis
(Figure 4(b)). Although this strain could completely utilize
5% (w/v) glucose in a mineral salts medium with a yield
near theoretical maximum (96%), the volumetric D-lactate
productivity of 0.42 g/L/h was relatively low compared with
lactic acid bacteria [35]. In addition, this strain can neither
utilize sucrose nor completely utilize 10% (w/v) sugar [35].
Therefore, an E. coli W derivative strain was chosen as
chassis for more robust D-lactate production [35, 105]. After
redesigning central metabolism so that D-lactate production
was the sole means of oxidizing NADH, metabolic evolution
was used to further improve cell growth and D-lactate pro-
ductivity. The resulting strain, SZ194, eﬃciently consumed
12% (w/v) glucose in mineral salts medium and produced
110 g/L D-lactate [105] with a volumetric productivity of
2.14 g/L/h, a 5-fold increase over the W3110 derivative. The
biocatalyst was further optimized by deleting methylglyoxal
synthase gene (mgsA) to eliminate L-lactate production, and
by metabolic evolution to increase yield and productivity.
The final D-lactate producing strain, TG114, could convert
12% (w/v) glucose to 118 g/L D-lactate with an excellent yield
(98%) and productivity (2.88 g/L/h) [22].
3.3. Acetate. Acetate is a commodity chemical with 2001
worldwide production estimated at 6.8 million metric tons
[23]. Biological production of acetate accounts for only 10%
of world production, mainly in the form of vinegar, with
the remainder of production through petrochemical routes
[106–108]. Biological production of commodity chemicals
has historically focused on anaerobic production of reduced
products, since substrate loss as cell mass and CO2 is minimal
and product yields are high. Contrastingly, acetate is an
oxidized chemical, and traditional biological production
involves a complex two-stage process: fermentation of sugars
to ethanol by Saccharomyces, followed by aerobic oxidation
of ethanol to acetate by Acetobacter [106–108]. To enable
microbial production of redox-neutral or oxidized products
at high yield, the biocatalyst metabolism needs to be
redesigned to combine attributes of both fermentative and
oxidative metabolisms.
Redesign of E. coli W3110 metabolism for acetate
production focused on three major pathways: fermenta-
tive metabolism, oxidative metabolism, and energy supply
(Figure 4(c)) [23]. The competitive fermentation pathways
(pflB, ldhA, frd, adhE) were inactivated to prevent the con-
sumption of common precursor pyruvate, and the oxidative
tricarboxylic acid (TCA) cycle was interrupted to reduce
the carbon loss as CO2. Finally, oxidative phosphorylation
was disrupted (atpFH) to reduce ATP production while
maintaining the ability to oxidize NADH by the electron
transport system, thus increasing the glycolytic flux for more
ATP production through substrate-level phosphorylation.
Although rationally designed, the resulting strain, TC32,
had an undesirable auxotrophic requirement for succinate
during growth in glucose-minimal medium. Evolution was
used to eliminate this auxotrophy and the final strain, TC36,
produced 878 mM acetate (53 g/L) in mineral salts medium
with 75% of the maximal theoretical yield. Although this is
a lower titer than acetate produced from ethanol oxidation
by Acetobacter, TC36 has a two-fold higher production rate,
requires only mineral salts medium, and can metabolize a
wide range of carbon sources in a simple one-step process
[23].
3.4. Others. Butanol is an excellent alternative transportation
fuel with several advantages compared to ethanol, including
higher-energy content, lower volatility, less hydroscopicity,
and less corrosivity [109]. Redesign of E. coli for butanol
production is discussed below. C. acetobutylicum ATCC 824
naturally produces butanol and was redesigned to increase
butanol production and decrease coproduct accumulation.
Metabolic engineering-type modifications, such as over-
expression of the acetone formation pathway to increase
formation of butanol precursor butyryl-CoA, inactivation
of the transcriptional repressor SolR, and overexpression
of alcohol/aldehyde dehydrogenase all increased butanol
production [110–112]. In an excellent example of synthetic
biology-type applications, expression of the butyrate kinase
gene was fine-tuned by a rationally designed antisense RNA
to increase butanol production [113].
1,2-propanediol (1,2-PD) is a major commodity chem-
ical currently derived from propylene. E. coli naturally pro-
duces low amounts of 1,2-PD, and therefore its metabolism
was redesigned to produce 1,2-PD at high yield and titer
from glucose this was achieved by inactivation of com-
peting pathways (lactate dehydrogenase and glyoxalase I),
and overexpression of essential genes of 1,2-PD synthetic
pathway (methylglyoxal synthase, glycerol dehydrogenase,
and 1,2-PD oxidoreductase) [114]. Evolution was also used
in combination with rational design for increased 1,2-PD
production [115].
L-valine, an essential hydrophobic and branched-chain
amino acid, is used in cosmetics, pharmaceuticals, and
animal feed additives [116]. E. coli was redesigned for L-
valine production at high yield and titer from glucose
through a combination of traditional metabolic engineering
and synthetic biology. Traditional metabolic engineering
was used to inactivate competing pathways and overexpress
acetohydroxy acid synthase I (ilvBN), part of the valine
biosynthesis pathway. Unfortunately, the E. coli chassis has
regulatory elements that tightly control L-valine biosynthe-
sis, making production of valine at high yield and titer
diﬃcult. Feedback inhibition was eliminated by rational site-
directed mutagenesis of acetohydroxy acid synthase III. In
an excellent demonstration of the gene expression tuning
techniques discussed above, transcriptional attenuation of
valine biosynthesis genes ilvGMEDA was eliminated by
replacing the attenuator leader region with the constitutive
tac promoter. Transcriptome analysis and in silico simulation
guided selection of additional target genes for amplification
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and deletion, and the final biocatalyst produced 0.378 g L-
valine per g glucose, giving a titer of 7.55 g/L valine from
20%(w/v) glucose [116]. A similar strategy was also used for
L-threonine production [117].
4. Redesign through Introduction of
Foreign or Nonnatural Pathways
4.1. Foreign Pathways
4.1.1. Ethanol. Ethanol is a renewable transportation fuel.
Replacement of gasoline with ethanol would significantly
reduce US import oil dependency, increase the national secu-
rity, and reduce environmental pollution [118]. However,
only 9 billion gallons of ethanol were produced in 2008,
and all were from corn-based production. Lignocellulose
is generally regarded as an excellent source of sugars for
conversion into fuel ethanol. It is, thus, desirable to design or
obtain biocatalysts that can utilize all the sugar components
in lignocellulose and convert them to ethanol with high yield
and productivity in mineral salts medium. Native S. cere-
visiae and Z. mobilis strains can eﬃciently convert glucose to
ethanol, but cannot utilize pentose sugars. In contrast, E. coli
strains can utilize all the sugar components of lignocelluloses
but ethanol is only a minor fermentation product, with
mixed acids accumulating as the major fermentation product
[103]. While recent advances have been made engineering
the native E. coli metabolic pathways for ethanol production
[119], the most successful example used a foreign metabolic
pathway to enable ethanol production from E. coli strain W
(ATCC# 9637) [1].
Redesign for ethanol production was decoupled to three
parts: construction of a metabolic pathway for production
of ethanol as the major fermentation product, elimination
of competitive NADH oxidization pathways, and disruption
of side-product formation. The Z. mobilis homoethanol
pathway (pyruvate decarboxylase and alcohol dehydro-
genase) was introduced as a foreign pathway, enabling
redox-balanced production of ethanol at high yield [120]
(Figure 4(b)). Then fumarate reductase (frd) was disrupted
to increase ethanol yield. The resulting strain, KO11, pro-
duced ethanol at a yield of 95% in a complex medium
[121]. This strain was developed at the dawn of metabolic
engineering and has been used to produce ethanol from a
variety of lignocellulosic materials, as reviewed in [1].
Although the ethanol production rate of KO11 was
as high as yeast, the ethanol tolerance and performance
in minimal medium did not meet the desired standards.
Therefore strain SZ110, a derivative of KO11 modified
for lactate production in mineral salts media [35], was
redesigned for ethanol production [122]. As with the design
of KO11, redesign of SZ110 was decoupled to construction
of an ethanol synthetic pathway, elimination of compet-
itive NADH oxidization pathways, and blockage of side-
product formation. However, this redesign strategy also
included the acceleration of mixed sugar co-utilization. The
lactate producing pathway was disrupted and the Z. mobilis
homoethanol pathway was integrated into the chromosome
by random insertion to select for optimal expression. The
Pseudomonas putida short-chain esterase (estZ) [123] was
introduced to decrease ethyl acetate levels in the fermenta-
tion broth and decrease the downstream purification cost.
In addition, methylglyoxal synthase (mgsA) was inactivated,
resulting in co-metabolism of glucose and xylose, and
accelerated the metabolism of a 5-sugar mixture (mannose,
glucose, arabinose, xylose, and galactose) to ethanol [25].
After using evolution to increase cell growth and production,
the final strain, LY168, could concurrently metabolize a
complex combination of the five principal sugars present in
lignocellulosic biomass with a high yield and productivity in
mineral salts medium [25].
4.1.2. L-Lactate. As described above, L-lactate is the major
component of the biodegradable plastic PLA. Although
many lactic acid bacteria produce L-lactate with high
yield and productivity [124], they usually require complex
nutrients. E. coli does not have a native pathway for L-lactate
production, and therefore introduction of a foreign pathway
was necessary.
The strategy for redesigning E. coli W3110 for L-lactate
production was to eliminate competitive NADH oxidization
pathways and then construct the desired L-lactate syn-
thetic pathway (Figure 4(b)) [125]. The L-lactate production
pathway, L-lactate dehydrogenase (ldhL) from Pediococcus
acidilactici, was used and its coding region and terminator
were integrated into the E. coli chromosome at the ldhA
site, so that ldhL could be expressed under the native ldhA
promoter. In addition, since the ldhL gene contains a weak
ribosomal-binding region, this region was rationally replaced
with ldhA’s RBS [125]. Following a period of metabolic
evolution, the resulting strain, SZ85, synthesized 45 g/L L-
lactate in a mineral salts medium with yield near theoretical
maximum (94%). However, this strain was a K-12 derivative
and displayed the same problems seen with the K12-based
D-lactate-producing strain described above, meaning that it
was unable to completely ferment high sugar concentrations
and had a low productivity (0.65 g/L/h). Therefore, the same
design strategy was implemented in an E. coli W (ATCC#
9637) derivative. After further deleting mgsA gene to improve
chiral purity and using metabolic evolution to improve
cell growth and productivity, the final L-lactate-producing
strain, TG108, could convert 12% glucose to 116 g/L L-lactate
with an excellent yield (98%) and productivity (2.29 g/L/h)
[22].
4.1.3. Xylitol. The pentahydroxy sugar alcohol xylitol is
commonly used to replace sucrose in food and as a natural,
non-nutritive sweetener that inhibits dental caries [126].
Xylitol can also be used as a building block for synthesizing
new polymers [127]. Current xylitol commercial production
involves hydrogenation of hemicellulose-derived xylose with
an active metal catalyst [127]. Biological-based processes
have also recently been developed, but although high xylitol
titer was achieved by some yeast, the process requires com-
plex medium with numerous expensive vitamin supplements
[128]. While E. coli does not have the native capability to
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synthesize xylitol, a redesign strategy for strain W3110 was
proposed involving a foreign metabolic pathway [26]. In the
proposed redesign, glucose would support cell growth and
provide reducing equivalents, while xylose would be used
as substrate for xylitol synthesis (Figure 4(d)). The design
strategy consisted of three major components: enabling
co-utilization of glucose and xylose, separation of xylose
metabolism from central metabolism, and construction
of a xylitol production pathway (Figure 4(d)). In order
to enable co-utilization of glucose and xylose, glucose-
mediated repression of xylose metabolism was eliminated
by replacing the native crp gene with a cAMP-independent
mutant (CRP∗). Xylose metabolism was separated from
central metabolism by deleting the xylulokinase (xylB) gene,
preventing the loss of xylose carbon to central metabolism.
Finally, xylose reductase and xylitol dehydrogenase from
several microorganisms were tested for xylitol synthetic
capability, and the NADPH-dependent xylose reductase
from C. boidinii (CbXR) was found to support optimal
xylitol production. The final strain, PC09 (CbXR), could
produce 250 mM (38 g/L) xylitol in mineral salts medium.
The yield was 1.7 mol xylitol per mol glucose consumed,
which was improved to 4.7 mol/mol by using resting cells.
It was proposed that xylitol production could be further
improved by increasing supply of reducing equivalents
[129].
4.1.4. L-Alanine. L-alanine can be used with other L-amino
acids as a pre- and postoperative nutrition therapy in
pharmaceutical and veterinary applications [130]. It is also
used as a food additive because of its sweet taste. The annual
worldwide production of L-alanine is around 500 tons [131],
and this market is currently limited by production costs. The
current commercial production process converts aspartate
to alanine via aspartate decarboxylase, where aspartate is
produced from fumarate by aspartate ammonia-lyase catal-
ysis [27]. An eﬃcient fermentative process with a renewable
feedstock such as glucose oﬀers the potential to reduce L-
alanine cost and facilitate a broad expansion of the alanine
market into other products.
SZ194, a derivative of E. coli W (ATCC# 9637) that was
previously engineered for D-lactate production, was used
as the chassis for L-alanine production [27] (Figure 4(b)).
Alanine production in the native strain uses glutamate- and
NADPH-dependent glutamate-pyruvate aminotransferase.
It is preferable to produce L-alanine directly from pyruvate
and ammonia using an NADH-dependent enzyme, and
therefore L-alanine dehydrogenase (alaD) of Geobacillus
stearothermophilus was employed. The native ribosome bind-
ing site, coding region, and terminator of alaD gene were
integrated into the E. coli chromosome at the ldhA site, so
that expression of alaD could be controlled by the native
promoter of ldhA, a promoter that has worked well for
production of D- and L-lactate, as described above. Further
redesign focused on elimination of trace amounts of lactate
and increasing the L-alanine chiral purity by deleting mgsA
and the major alanine racemase gene (dadX). Metabolic
evolution increased the final titer and productivity by 15-
and 30-fold, respectively (Figure 3). The latest L-alanine
producing strain, XZ132, converted 12% glucose to 114 g/L
L-alanine with a 95% yield and the excellent volumetric
productivity of 2.38 g/L/h [27].
4.1.5. Combining Multiple Foreign Pathways in a Single
Chassis. Although the work described above relied on the
introduction of a single foreign pathway, there are other
excellent examples that employ pathways from more than
one organism in a single host.
E. coli was redesigned for 1,3-propanediol production
using S. cerevisiae pathway to convert glucose to glycerol
and a K. pneumonia pathway to convert glycerol to 1,3-
propanediol [132]. E. coli was also redesigned for isopro-
panol production by combining acetyl CoA acetyltransferase
(thl) and acetoacetate decarboxylase (adc) from C. aceto-
butylicum with the second alcohol dehydrogenase (adh) from
C. beijerinckii and E. coli’s own acetoacetyl-CoA transferase
(atoAD) [133]. Artemisinic acid, a precursor of antimalarial
drug artemisin, was produced by E. coli following the
combination of a mevalonate pathway from S. cerevisiae
and E. coli, amorphadiene synthase, and a novel cytochrome
P450 monooxygenase (CYP71AV1) from Artemisia annua
[12, 134].
S. cerevisiae was redesigned for flavanone production
by combining Arabidopsis thaliana cinnamate 4-hydroxy-
lase (C4H), Petroselinum crispum 4-coumaroyl: CoA-ligase
(4CL), and Petunia chalcone synthase (CHS), Petunia chal-
cone isomerase (CHI) [135]. A similar synthetic system
producing hydroxylated flavonols was also constructed in
E. coli with additional amplification of C. roseus P450
flavonoid 3′, 5′-hydroxylase (F3′5′H) fused with P450 re-
ductase, Malus domestica flavanone 3β-hydroxylase (FHT),
and Arabidopsis thaliana flavonol synthase (FLS) [136]. The
flavonoid production was significantly increased through
further redesigning of the central metabolic system of E. coli
to increase precursor (Malonyl-CoA) supply [137].
4.2. Modification of Natural Pathways for Production of
Unnatural Compounds. One of the goals of synthetic biology
is to design or construct new genetic circuits. In the examples
given thus far, existing biological parts have been reassem-
bled to engineer a biocatalyst that eﬃciently produces a
product that already exists in nature. However, metabolic
pathways can also be constructed to produce unnatural
compounds.
As discussed above, directed evolution of proteins can
modify their activity such that new substrates are recognized
or new products are formed [138]. For example, novel
carotenoid compounds were generated by evolution of two
key carotenoid synthetic enzymes, phytoene desaturase, and
lycopene cyclase [139]. Additionally, combinatorial biosyn-
thesis, which combines genes from diﬀerent organisms into
a heterologous host, can also generate new products [140].
For example, four previously unknown carotenoids were
produced by combinatorial biosynthesis in E. coli [141].
4.3. De Novo Pathway Design. In order to broaden the avail-
able biosynthesis space, it is essential to go beyond the natural
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pathways and design pathways de novo [142]. Although this
exciting design strategy still has many challenges, several
successful examples have been reported.
For example, a synthetic pathway for 3-hydroxypropionic
acid (3-HP) production was designed involving the unnat-
ural isomerization of α-alanine to β-alanine, as mentioned
above. In this example the researchers used directed evo-
lution to expand the substrate specificity of lysine 2,3-
aminomutase to include α-alanine [73]. The resulting β-
alanine can then be converted to 3-HP through existing
metabolic pathways.
Unnatural pathways for higher alcohol production
in E. coli were designed by combining the native amino
acid synthetic pathways with a 2-keto acid decarboxylase
from Lactococcus lactis and alcohol dehydrogenase from S.
cerevisiae [143]. The 2-keto acid intermediates in amino
acid biosynthesis pathways were redirected from amino acid
production to alcohol production, enabling production of
3-methyl-1-pentanol. This pathway was then expanded for
production of unnatural alcohols by rational redesign of two
enzymes, with the resulting biocatalysts having the ability
to synthesize various unnatural alcohols ranging in length
from five to eight carbons [144].
4.4. Engineering Tolerance to Inhibitory Compounds. As our
repertoire of biologically-produced compounds increases,
tolerance to high product titers becomes more important.
Biofuels, such as ethanol and butanol, can inhibit biocatalyst
growth, and therefore the tolerance of the biocatalyst needs
to be improved [145–147]. As described above, our goal is to
use lignocellulosic biomass as a substrate for production of
commodity fuels and chemicals. Unfortunately, the processes
used to convert biomass to soluble sugars also produce a
mixture of minor products, such as furfural and acetic acid,
that inhibit biocatalyst metabolism [148]. Although most of
these inhibitors could be removed by detoxification [149],
this additional process would increase operational cost. It is,
thus, desirable to obtain microorganisms that are tolerant
to these inhibitors and can directly ferment hemicellulose
hydrolysate.
One approach to increasing tolerance is to understand
the mechanism of inhibition. Transcriptome analysis has
been used to probe the response to ethanol [145, 150],
furfural [151], and butanol [147]. Another approach is
to use directed evolution, as highlighted by the following
example. Ethanologenic E. coli strain LY180 (a derivative
of LY168 with restored lactose utilization and integration
of an endoglucanase, and cellobiose utilization) was used
as the chassis to select for furfural resistance through evo-
lution [148]. The evolved strain, EMFR9, had significantly
increased furfural resistance. Reverse engineering eﬀorts,
including transcriptome analysis, attributed furfural resis-
tance to the silencing expression of several oxidoreductases.
These oxidoreductases use NADPH for furfural reduction,
depleting the available pools for biosynthesis. Thus furfural-
mediated growth inhibition can be attributed to NADPH
depletion [148], an insight that can be applied to other
biocatalyst design projects.
5. Perspectives
Although many biocatalysts have been successfully rede-
signed for production of industrially important fuels and
chemicals through traditional metabolic engineering, we are
just beginning to see the potential of synthetic biology in this
area. One of the foremost goals in our lab is the improvement
of biocatalysts for biomass utilization. To attain this goal,
tolerance to hydrolysate-derived inhibitors needs to be
improved. For all applications, tolerance to high substrate
and product titers is also important. This goal of redesigning
a biocatalyst’s phenotype, that is, tolerance, is not as clear
as redesigning metabolism and a rational redesign strategy
is particularly diﬃcult when the mechanism of inhibition is
not known.
As the understanding of our biocatalysts improves,
particularly through reverse engineering of evolved strains,
genome-scale models can be improved. Inclusion of kinetic
and regulatory eﬀects will also improve the accuracy and
predictive power of these models. Note that some models
have recently been developed that bypass the need for kinetic
data, though [152]. Since enzymes are the major functional
part performing the metabolic synthesis, improved protein
engineering tools and new protein catalytic capability will
aid in advancement of this field. It is important to generate
high-quality protein mutagenesis libraries (relatively small
libraries with a high diversity of enzymes) to facilitate
eﬃcient screening eﬀorts [138]. Direct screening from
metagenomic libraries of environmental samples can aid
in isolation of enzymes with new functions, which cannot
be obtained by the traditional strain isolation methods
[153]. Enzymes can even be synthesized from scratch by
a rational design strategy with computational aid [154].
Finally, new tools for better de novo design of synthetic
pathways need to be developed. Several databases, such
as BNICE (Biochemical Network Integrated Computational
Explorer) [155] and ReBiT (Retro-Biosynthesis Tool) [142],
have already been established to facilitate identification of
enzymes to construct a complete synthetic pathway for
producing target compounds. It is important to establish
guidelines, such as redox balance, energy production, and
thermodynamic feasibility, to screen among these enormous
pathways for the optimal routes.
By including synthetic biology tools in metabolic engi-
neering projects, and vice versa, these two fields can signifi-
cantly advance the replacement of petroleum-derived com-
modity products with those produced from biorenewable
carbon and energy.
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